{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:47:09Z","timestamp":1784202429291,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12029-023-00946-z","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T06:02:25Z","timestamp":1687845745000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers"],"prefix":"10.1007","volume":"55","author":[{"given":"Sandeep","family":"Gedela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh","family":"Munot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritam","family":"Joarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Chaugule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitali","family":"Nashikkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayushi","family":"Ghadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Vadodaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Mandavkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"30","key":"946_CR1","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30):4581\u20136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"946_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/cncr.21591","volume":"104","author":"JY Cho","year":"2005","unstructured":"Cho JY, Paik YH, Chang YS, Lee SJ, Lee D-K, Song SY, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma. Cancer. 2005;104(12):2753\u20138.","journal-title":"Cancer"},{"issue":"10","key":"946_CR3","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(10):2332\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"946_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","volume":"99","author":"T Andr\u00e9","year":"2008","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862\u20137.","journal-title":"Br J Cancer"},{"issue":"14","key":"946_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"6","key":"946_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","journal-title":"JAMA Oncol"},{"key":"946_CR7","doi-asserted-by":"crossref","unstructured":"Rachna T. Shroff, MD, SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. ASCO GI Cancer Symposium 2023.","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490"},{"issue":"6","key":"946_CR8","first-page":"99","volume":"7","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;7(6):99\u2013109.","journal-title":"Clin Epidemiol"},{"issue":"7","key":"946_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ijc.21683","volume":"118","author":"G Randi","year":"2006","unstructured":"Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591\u2013602.","journal-title":"Int J Cancer"},{"key":"946_CR10","doi-asserted-by":"publisher","unstructured":"Murthy NS, Rajaram D, Gautham M, Shivraj N, Pruthvish S, George PS, Mathew A. Trends in incidence of gallbladder cancer \u2013 Indian scenario. Gastrointestinal Cancer: Targets and Therapy. 2011;1:1\u20139. https:\/\/doi.org\/10.2147\/GICTT.S16578.","DOI":"10.2147\/GICTT.S16578"},{"issue":"11","key":"946_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984;2(11):1245\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"946_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008241008379","volume":"9","author":"M Ducreux","year":"1998","unstructured":"Ducreux M, Rougier P, Fandi A, Clavero-Fabri M-C, Villing A-L, Fassone F, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9(6):653\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"946_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374.","journal-title":"Br J Cancer"},{"issue":"34","key":"946_CR14","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29(34):4548\u201354. https:\/\/doi.org\/10.1200\/JCO.2011.36.5742.","journal-title":"J Clin Oncol"},{"key":"946_CR15","doi-asserted-by":"publisher","unstructured":"Cheon J, Lee C, Sang YB, et al. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Ther Adv Med Oncol. 2021;13. https:\/\/doi.org\/10.1177\/17588359211035983.","DOI":"10.1177\/17588359211035983"},{"issue":"21","key":"946_CR16","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","volume":"28","author":"AF Hezel","year":"2010","unstructured":"Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28(21):3531\u201340.","journal-title":"J Clin Oncol"},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2407-11-60","volume":"11","author":"V Deshpande","year":"2011","unstructured":"Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, MacConaill LE, Lauwers GY, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60.","journal-title":"BMC Cancer"},{"issue":"12","key":"946_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/hpb.12504","volume":"17","author":"M Potkonjak","year":"2015","unstructured":"Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, et al. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB. 2015;17(12):1119\u201323.","journal-title":"HPB"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-00946-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00946-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:33:07Z","timestamp":1715761987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-00946-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-00946-z","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"21 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}